Custom Manufacturing, Project Outsourcing, your Trusted Partner from China
NINGBO INNO PHARMCHEM CO.,LTD. is dedicated to advancing pharmaceutical science and providing access to critical compounds that drive innovation. Today, we focus on Tegoprazan (CAS 942195-55-3), a potent potassium-competitive acid blocker (P-CAB) that is revolutionizing the treatment landscape for gastrointestinal disorders. Understanding the intricate science behind this molecule is key to appreciating its therapeutic value.
The core of Tegoprazan's efficacy lies in its role as a Tegoprazan H+/K+-ATPase inhibitor. Unlike conventional proton pump inhibitors (PPIs) that require acidic activation, Tegoprazan directly binds to the proton pump in gastric parietal cells. This direct interaction allows for a rapid and dose-dependent inhibition of acid secretion, offering faster symptom relief for patients experiencing conditions such as peptic ulcers. When considering Tegoprazan for peptic ulcer treatment, its direct mechanism offers a distinct advantage.
The development of P-CABs like Tegoprazan was motivated by the limitations of existing PPIs, including variability in patient response and incomplete nocturnal acid control. Tegoprazan's reversible binding kinetics and its ability to maintain intragastric pH above 4 for extended periods address these issues effectively. The comparative studies highlighting Tegoprazan vs PPI efficacy often point to its more robust and sustained acid suppression capabilities, making it an attractive option for managing challenging gastrointestinal conditions.
As a key player in the supply chain for pharmaceutical ingredients, NINGBO INNO PHARMCHEM CO.,LTD. emphasizes the importance of quality and consistency when clients seek to buy Tegoprazan API. Our meticulous quality control processes ensure that the Tegoprazan pharmaceutical intermediate we provide meets the highest purity standards required for drug formulation and research. The ongoing exploration of Tegoprazan drug development continues to reveal new therapeutic avenues and confirmations of its promising Tegoprazan safety profile.
The scientific community is keenly observing the results from various Tegoprazan clinical trials, which provide robust data on its performance in treating a spectrum of acid-related diseases. Its potential role in combination therapies, particularly for eradicating resistant strains of Helicobacter pylori, further underscores its versatility and importance in modern medicine. The unique Tegoprazan mechanism of action is a subject of continuous study, promising further insights into optimizing its clinical utility.
NINGBO INNO PHARMCHEM CO.,LTD. is proud to support the advancement of gastrointestinal health through the provision of high-quality Tegoprazan. We are committed to fostering a deeper understanding of this vital compound and its impact on patient care, ensuring that the pharmaceutical industry has access to the essential components for developing next-generation therapies.
Manufacturing Facilities
Professional Export Experience
to Global Customers
1. 20 years of R&D, manufacturing and sales experience, serving customers in 60 countries and regions around the world;
2. Own R&D laboratory, pilot platform and large-scale production workshop, which can meet the audit requirements of global customers;
3. We can satisfy customers' perfect transition from small scale lab requirements (gram level) to commercialization requirements (hundred tons level).
A: We don't have Minimum Order Quantity, exact quantity should be provided before quotation for us to calculate the exact cost.
A: We don't provide free samples due to lots of request and expensive international courier's cost, we can deduct the sample charge after commercial order placed.
A: Our payment terms: Small or sample order: T/T IN ADVANCE. Commercial order: First order should be by T/T IN ADVANCE or L/C at sight, and following orders T/T 30~90days is acceptable subject to approval of credit application.
